Medtronic Claims Clinical, Cost Advantages For Just-Launched Viva CRT-D
This article was originally published in The Gray Sheet
Executive Summary
Viva is the first of Medtronic’s U.S. CRT-Ds to incorporate the proprietary AdaptivCRT algorithm designed to more readily adapt to a patient’s condition and optimize therapy. The firm also launched its Evera ICD last week.